In a strategic move to address the surging global interest in nasal drug delivery, contract development and manufacturing organizations (CDMOs) Bespak and Upperton Pharma Solutions have announced a formal collaboration. This partnership aims to bridge the long-standing disconnect between drug formulation and device engineering, providing pharmaceutical developers with a unified pathway for bringing complex nasal drug-device combination products to market.
As the pharmaceutical industry shifts toward non-invasive alternatives to injections and oral medications, the demand for sophisticated nasal delivery systems has reached a fever pitch. However, developers have historically faced significant hurdles in coordinating between independent formulation experts and hardware manufacturers. The Bespak-Upperton alliance is designed to mitigate these challenges by synchronizing Bespak’s extensive expertise in nasal device engineering and commercial-scale manufacturing with Upperton’s specialized formulation development and analytical capabilities.
The combined service offering covers the full lifecycle of a nasal product, supporting a wide range of formats including liquid, soft mist, and dry powder formulations. This integration is centered around Bespak’s newly expanded portfolio of proprietary single-dose and multi-dose nasal devices. By engaging both formulation and device specialists from the earliest stages of a project, the companies intend to streamline development cycles, reduce technical risk, and accelerate the transition from concept to clinical supply and full-scale commercialization.
“Our collaboration with Upperton adds highly complementary formulation and analytical expertise to our expanded nasal device portfolio, giving customers a more integrated development pathway,” said Chris Hirst, CEO of Bespak. “By considering the formulation and device as one combination product from an early stage, we can help customers navigate development more efficiently and build a stronger foundation for clinical and commercial success.”
For drug developers, the complexity of aligning various suppliers has often led to bottlenecks, particularly during the transition from the laboratory bench to large-scale industrialization. This partnership promises to dismantle those silos, offering a “one-stop” resource that handles everything from the initial drug-device assessment through to clinical trial support and final market supply.
Nikki Whitfield, CEO of Upperton, emphasized that the collaboration is fundamentally about improving the developer experience. “By combining Upperton’s formulation, analytical and clinical manufacturing expertise with Bespak’s device engineering and commercialization capabilities, we can provide customers with coordinated support across the entire development journey,” Whitfield noted.
Industry analysts suggest that this collaborative model represents a growing trend in the CDMO space, where the value proposition is shifting from providing individual services to offering integrated, end-to-end solutions. As regulatory requirements for combination products become more stringent, the ability of Bespak and Upperton to offer a seamless, synchronized development track is expected to be a significant competitive advantage for pharmaceutical firms looking to capture market share in the rapidly evolving nasal delivery landscape.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
